The syndrome of inappropriate secretion of antidiuretic hormone: Diagnostic and therapeutic advances

Hormone and Metabolic Research

Volumn 42, Issue 10, 2010, Pages 691-702

  Fenske, W ^a   Allolio, B ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

diagnostic approach; hyponatremia; SIADH; treatment of hyponatremia; vasopressin receptor antagonists

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CLOFIBRATE; CONIVAPTAN; CYCLOPHOSPHAMIDE; DEMECLOCYCLINE; DESMOPRESSIN; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; LITHIUM CARBONATE; LIXIVAPTAN; LOOP DIURETIC AGENT; NARCOTIC AGENT; NEUROLEPTIC AGENT; NICOTINE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYTOCIN; PROSTAGLANDIN INHIBITOR; SATAVAPTAN; SEROTONIN UPTAKE INHIBITOR; SODIUM CHLORIDE; TOLVAPTAN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UREA; VAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR ANTAGONIST; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; ANEMIA; ANTIDIURESIS; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; FATIGUE; HUMAN; HYPOKALEMIA; HYPONATREMIA; HYPOTHYROIDISM; HYPOVOLEMIA; INAPPROPRIATE VASOPRESSIN SECRETION; INDUCED HYPOTENSION; KIDNEY FAILURE; LONG TERM CARE; LUNG DISEASE; LUNG EDEMA; NAUSEA; NEPHROGENIC DIABETES INSIPIDUS; NEPHROTOXICITY; NEUROLOGIC DISEASE; NONHUMAN; OSMOLALITY; PATHOPHYSIOLOGY; POLLAKISURIA; POLYDIPSIA; POLYURIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHORT COURSE THERAPY; SIDE EFFECT; SKIN PHOTOSENSITIVITY; SUPERINFECTION; THIRST; TREATMENT DURATION; TREATMENT INDICATION; TUMOR; URINALYSIS; URINARY TRACT INFECTION; VASCULAR DISEASE; XEROSTOMIA;

ANIMALS; HUMANS; HYPONATREMIA; INAPPROPRIATE ADH SYNDROME;

EID: 77956432007     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0030-1255117     Document Type: Review

References (97)

1. Bartter FC, Schwartz WB. The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967 42 790-806
2. Sims EA, Welt LG, Orloff J, Needham JW. Asymptomatic hyponatremia in pulmonary tuberculosis. J Clin Invest 1950 29 1545-1557
3. Winkler AW, Crankshaw OF. Chloride Depletion in Conditions Other Than Addison's Disease. J Clin Invest 1938 17 1-6
4. Cheek DB, West CD, Golden CC. The distribution of sodium and chloride and the extracellular fluid volume in the rat. J Clin Invest 1957 36 340-351
5. Finberg L. Factors affecting prognosis of tuberculous meningitis treated with streptomycin. Pediatrics 1951 8 768-771
6. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med 1957 23 529-542
7. Ragnarsson U. The Nobel trail of Vincent du Vigneaud. J Pept Sci 2007 13 431-433
8. Robertson GL, Mahr EA, Athar S, Sinha T. Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma. J Clin Invest 1973 52 2340-2352
9. Upadhyay A, Jaber BL, Madias NE. Epidemiology of hyponatremia. Semin Nephrol 2009 29 227-238
10. Gross P. Treatment of hyponatremia. Intern Med 2008 47 885-891
11. Ellison DH, Berl T. Clinical practice. The syndrome of inappropriate antidiuresis. N Engl J Med 2007 356 2064-2072
12. Saito T, Ishikawa S, Abe K, Kamoi K, Yamada K, Shimizu K, Saruta T, Yoshida S. Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Clin Endocrinol Metab 1997 82 1054-1057
13. Wong F, Blei AT, Blendis LM, Thuluvath PJ. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial. Hepatology 2003 37 182-191
14. Soupart A, Gross P, Legros JJ, Alfoldi S, Annane D, Heshmati HM, Decaux G. Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006 1 1154-1160
15. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006 355 2099-2112
16. Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007 297 1319-1331
17. Verbalis JG. Syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Schrier RW (ed). Diseases of the Kidney and Urinary Tract. 8th ed. Philadelphia Lippincott Williams & Wilkins 2007 Vol. III, Chap. 86
18. Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R. Molecular pharmacology of human vasopressin receptors. Adv Exp Med Biol 1998 449 251-276 (Pubitemid 28566397)
19. Thibonnier M. Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists. Expert Opin Investig Drugs 1998 7 729-740
20. Knepper MA. Molecular physiology of urinary concentrating mechanism: regulation of aquaporin water channels by vasopressin. Am J Physiol 1997 272 F3-F12
21. Schrier RW. The sea within us: disorders of body water homeostasis. Curr Opin Investig Drugs 2007 8 304-311
22. Morgan DB, Thomas TH. Water balance and hyponatraemia. Clin Sci (Lond) 1979 56 517-522
23. Robertson GL. Regulation of arginine vasopressin in the syndrome of inappropriate antidiuresis. Am J Med 2006 119 S36-S42
24. Schrier RW. Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 2006 17 1820-1832
25. Schwartz WB, Bennett W, Curelop S, Bartter FC. A syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. 1957. J Am Soc Nephrol 2001 12 2860-2870
26. Stormont JM, Waterhouse C. Severe hyponatremia associated with pneumonia. Metabolism 1962 11 1181-1186
27. Walser M, Seldin DW, Grollman A. An evaluation of radiosulfate for the determination of the volume of extracellular fluid in man and dogs. J Clin Invest 1953 32 299-311
28. Burrows BA, Ross JF. The use of radioactive sodium and potassium: tracer studies in man. BMQ 1956 7 54-57
29. Verbalis JG. Pathogenesis of hyponatremia in an experimental model of the syndrome of inappropriate antidiuresis. Am J Physiol 1994 267 R1617-R1625
30. Kaye M. An investigation into the cause of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1966 41 910-926
31. Verbalis JG, Goldsmith SR, Greenberg A, Schrier RW, Sterns RH. Hyponatremia treatment guidelines 2007: expert panel recommendations. Am J Med 2007 120 S1-S21
32. Verbalis JG. Whole-body volume regulation and escape from antidiuresis. Am J Med 2006 119 S21-S29
33. Janicic N, Verbalis JG. Evaluation and management of hypo-osmolality in hospitalized patients. Endocrinol Metab Clin North Am 2003 32 459-481, vii
34. Chonchol M. Hyponatremia. In: DuBose TD (ed). Acid-base and electrolyte disorders: a companion to Brenner & Rector's The Kidney. Philadelphia Saunders 2002
35. Robertson GL, Shelton RL, Athar S. The osmoregulation of vasopressin. Kidney Int 1976 10 25-37
36. Noakes TD, Wilson G, Gray DA, Lambert MI, Dennis SC. Peak rates of diuresis in healthy humans during oral fluid overload. S Afr Med J 2001 91 852-857
37. Zerbe R, Stropes L, Robertson G. Vasopressin function in the syndrome of inappropriate antidiuresis. Annu Rev Med 1980 31 315-327
38. Michelis MF, Fusco RD, Bragdon RW, Davis BB. Reset of osmoreceptors in association with normovolemic hyponatremia. Am J Med Sci 1974 267 267-273
39. DeFronzo RA, Goldberg M, Agus ZS. Normal diluting capacity in hyponatremic patients. Reset osmostat or a variant of the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1976 84 538-542
40. Robertson GL, Athar S. The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 1976 42 613-620
41. Flear CT, Singh CM. Hyponatraemia and sick cells. Br J Anaesth 1973 45 976-994
42. Grantham JJ. Pathophysiology of hypoosmolar conditions: a cellular perspective. In: Andreoli TE Grantham JJ Rector FC Jr. (eds). Disturbances in body fluid osmolality. Bethesda, MD American Physiological Society 1977 217-225
43. Vincent JD, Arnauld E, Bioulac B. Activity of osmosensitive single cells in the hypothalamus of the behaving monkey during drinking. Brain Res 1972 44 371-384
44. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, Lustig RH, Mathias RS, Portale AA, Miller WL, Gitelman SE. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005 352 1884-1890
45. Robertson GL. The use of vasopressin assays in physiology and pathophysiology. Semin Nephrol 1994 14 368-383
46. Nielsen S, Marples D, Frokiaer J, Knepper M, Agre P. The aquaporin family of water channels in kidney: an update on physiology and pathophysiology of aquaporin-2. Kidney Int 1996 49 1718-1723
47. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of hospital-associated hyponatremia on selected outcomes. Arch Intern Med 2010 170 294-302
48. Gill G, Huda B, Boyd A, Skagen K, Wile D, Watson I, van Heyningen C. Characteristics and mortality of severe hyponatraemia - a hospital-based study. Clin Endocrinol (Oxf) 2006 65 246-249
49. Fenske W, Strk S, Allolio B. Limitations of the traditional diagnostic approach to hyponatremia. Am J Med 2010 in press
50. Clayton JA, Le Jeune IR, Hall IP. Severe hyponatraemia in medical in-patients: aetiology, assessment and outcome. QJM 2006 99 505-511
51. Hoorn EJ, Lindemans J, Zietse R. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. Nephrol Dial Transplant 2006 21 70-76
52. Arieff AI. Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women. N Engl J Med 1986 314 1529-1535
53. Turchin A, Seifter JL, Seely EW. Clinical problem-solving. Mind the gap. N Engl J Med 2003 349 1465-1469
54. Musch W, Hedeshi A, Decaux G. Low sodium excretion in SIADH patients with low diuresis. Nephron Physiol 2004 96 P11-P18
55. Chung HM, Kluge R, Schrier RW, Anderson RJ. Clinical assessment of extracellular fluid volume in hyponatremia. Am J Med 1987 83 905-908
56. McGee S, Abernethy WB 3rd, Simel DL. The rational clinical examination. Is this patient hypovolemic? JAMA 1999 281 1022-1029
57. Hoorn EJ, Zietse R. Hyponatremia revisited: translating physiology to practice. Nephron Physiol 2008 108 46-59
58. Musch W, Decaux G. Treating the syndrome of inappropriate ADH secretion with isotonic saline. QJM 1998 91 749-753
59. Fenske W, Stork S, Koschker AC, Blechschmidt A, Lorenz D, Wortmann S, Allolio B. Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics. J Clin Endocrinol Metab 2008 93 2991-2997
60. Curtis RH. Hyponatremia in primary myxedema. Ann Intern Med 1956 44 376-385
61. Warner MH, Holding S, Kilpatrick ES. The effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective study. Clin Endocrinol (Oxf) 2006 64 598-599
62. Croal BL, Blake AM, Johnston J, Glen AC, OReilly DS. Absence of relation between hyponatraemia and hypothyroidism. Lancet 1997 350 1402
63. Hoorn EJ, Halperin ML, Zietse R. Diagnostic approach to a patient with hyponatraemia: traditional versus physiology-based options. QJM 2005 98 529-540
64. Arlt W, Allolio B. Adrenal insufficiency. Lancet 2003 361 1881-1893
65. Smith JC, Siddique H, Corrall RJ. Misinterpretation of serum cortisol in a patient with hyponatraemia. BMJ 2004 328 215-216
66. Pura M, Kreze A Jr, Kentos P, Vanuga P. The low-dose (1 mug) Cosyntropin Test (LDT) for Primary Adrenocortical Insufficiency: Defining the Normal Cortisol Response and Report on First Patients with Addison Disease Confirmed with LDT. Exp Clin Endocrinol Diabetes 2010 118 151-157
67. Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med 2000 342 1581-1589
68. McKenna K, Thompson C. Osmoregulation in clinical disorders of thirst appreciation. Clin Endocrinol (Oxf) 1998 49 139-152
69. Gross P, Reimann D, Neidel J, Doke C, Prospert F, Decaux G, Verbalis J, Schrier RW. The treatment of severe hyponatremia. Kidney Int Suppl 1998 64 S6-S11
70. Palmer BF, Gates JR, Lader M. Causes and management of hyponatremia. Ann Pharmacother 2003 37 1694-1702
71. Hantman D, Rossier B, Zohlman R, Schrier R. Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline. Ann Intern Med 1973 78 870-875
72. Sterns RH, Cappuccio JD, Silver SM, Cohen EP. Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective. J Am Soc Nephrol 1994 4 1522-1530
73. Gankam Kengne F, Soupart A, Pochet R, Brion JP, Decaux G. Re-induction of hyponatremia after rapid overcorrection of hyponatremia reduces mortality in rats. Kidney Int 2009 76 614-621
74. Cherrill DA, Stote RM, Birge JR, Singer I. Demeclocycline treatment in the syndrome of inappropriate antidiuretic hormone secretion. Ann Intern Med 1975 83 654-656
75. Dousa TP, Wilson DM. Effects of demethylchlortetracycline on cellular action of antidiuretic hormone in vitro. Kidney Int 1974 5 279-284
76. Miller PD, Linas SL, Schrier RW. Plasma demeclocycline levels and nephrotoxicity. Correlation in hyponatremic cirrhotic patients. JAMA 1980 243 2513-2515
77. Curtis NJ, van Heyningen C, Turner JJ. Irreversible nephrotoxicity from demeclocycline in the treatment of hyponatremia. Age Ageing 2002 31 151-152
78. White MG, Fetner CD. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with lithium carbonate. N Engl J Med 1975 292 390-392
79. Juurlink DN, Mamdani MM, Kopp A, Rochon PA, Shulman KI, Redelmeier DA. Drug-induced lithium toxicity in the elderly: a population-based study. J Am Geriatr Soc 2004 52 794-798
80. Decaux G, Mols P, Cauchi P, Delwiche F. Use of urea for treatment of water retention in hyponatraemic cirrhosis with ascites resistant to diuretics. Br Med J (Clin Res Ed) 1985 290 1782-1783
81. Decaux G, Genette F. Urea for long-term treatment of syndrome of inappropriate secretion of antidiuretic hormone. Br Med J (Clin Res Ed) 1981 283 1081-1083 (Pubitemid 11017904)
82. Decaux G, Prospert F, Penninckx R, Namias B, Soupart A. 5-year treatment of the chronic syndrome of inappropriate secretion of ADH with oral urea. Nephron 1993 63 468-470
83. Soupart A, Schroeder B, Decaux G. Treatment of hyponatraemia by urea decreases risks of brain complications in rats. Brain osmolyte contents analysis. Nephrol Dial Transplant 2007 22 1856-1863
84. Berl T, Quittnat-Pelletier F, Verbalis JG, Schrier RW, Bichet DG, Ouyang J, Czerwiec FS. Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia. J Am Soc Nephrol 2010 21 705-710
85. Decaux G. Long-term treatment of patients with inappropriate secretion of antidiuretic hormone by the vasopressin receptor antagonist conivaptan, urea, or furosemide. Am J Med 2001 110 582-584
86. Annane D, Decaux G, Smith N. Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia. Am J Med Sci 2009 337 28-36
87. Zeltser D, Rosansky S, van Rensburg H, Verbalis JG, Smith N. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am J Nephrol 2007 27 447-457
88. Palm C, Pistrosch F, Herbrig K, Gross P. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia. Am J Med 2006 119 S87-S92
89. Madias NE. Effects of tolvaptan, an oral vasopressin V2 receptor antagonist, in hyponatremia. Am J Kidney Dis 2007 50 184-187
90. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008 371 1624-1632
91. Baylis PH. The syndrome of inappropriate antidiuretic hormone secretion. Int J Biochem Cell Biol 2003 35 1495-1499
92. Ghali JK, Koren MJ, Taylor JR, Brooks-Asplund E, Fan K, Long WA, Smith N. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J Clin Endocrinol Metab 2006 91 2145-2152
93. Mao ZL, Stalker D, Keirns J. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study. Clin Ther 2009 31 1542-1550
94. Murphy T, Dhar R, Diringer M. Conivaptan bolus dosing for the correction of hyponatremia in the neurointensive care unit. Neurocrit Care 2009 11 14-19
95. Gheorghiade M, Gottlieb SS, Udelson JE, Konstam MA, Czerwiec F, Ouyang J, Orlandi C. Vasopressin v (2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia. Am J Cardiol 2006 97 1064-1067
96. Decaux G. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 2001 138 18-21
97. Gerbes AL, Gulberg V, Gines P, Decaux G, Gross P, Gandjini H, Djian J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial. Gastroenterology 2003 124 933-939